ArticlePreventive medicine reports2018
Estimating lifetime and 10-year risk of lung cancer.
Article in Preventive medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Peutz-Jeghers Syndrome and lung cancer: does the risk meet the threshold for lung cancer screening?Familial cancer · 2026Review
- Article
- LDCT screening for lung cancer in East Asian never-smokers: balancing benefits and overdiagnosis-related harms.The Lancet regional health. Western Pacific · 2026Review
- Global Patterns and Trends in Lifetime Risks of Developing and Dying from Cancer, 1990-2021.Health data science · 2026Article
- Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Sex differences in bladder cancer: understanding biological and clinical implications.Biology of sex differences · 2025Review
- Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected.Frontiers in cellular and infection microbiology · 2024Review
- Assessment of Lifetime Risk for Cardiovascular Disease: Time to Move Forward.Current cardiology reviews · 2024Review
- Article
- Estimating 10-year risk of lung and breast cancer by occupation in Switzerland.Frontiers in public health · 2023Article
- Identification ofInternational journal of molecular sciences · 2022Article
- The spectrum of sex differences in cancer.Trends in cancer · 2022Review
- Distinct bronchial microbiome precedes clinical diagnosis of lung cancer.Molecular cancer · 2022Article
- Heavy Smoking Patients Receiving a Lung Cancer Screen Want to Quit: A Call for Tailored Cessation Interventions.Frontiers in medicine · 2022Article
- Gradus et al. Respond to "Machine Learning and Suicide Prevention: New Directions".American journal of epidemiology · 2021Article
- Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.Nature reviews. Clinical oncology · 2021Review
- Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the commonest cancer worldwide. Mortality and incidence rates are traditionally used to assess cancer burden and as public health indicators. However, these metrics are difficult to interpret at an individual level. Providing the lifetime and 10-year risks of cancer could improve risk communication. Our aim was to estimate current lifetime and 10-year risks of lung cancer by smoking status and changes in these risks between 1995 and 2013 in a Swiss population. We used all lung cancer cases recorded between 1995 and 2013 by two population-based cancer registries in the contiguous cantons of Vaud and Valais, in Western Switzerland. We estimated sex-specific lifetime risk and 10-year risk of lung cancer using the current probability method, accounting for competing risk of death. Estimates were also provided by smoking status. Between 1995 and 2013, 9623 cases of lung cancer were recorded. During this period, the lifetime risk decreased in men from 7.1% to 6.7% and increased in women from 2.5% to 4.1%. In both sexes, the 10-year risk of lung cancer increased with age until the age of 60-70 and decreased thereafter. Difference in the cumulative risk between current, former, and never smokers were very large and reported in user-friendly charts to ease risk communication. These lifetime and 10-year risk estimates could be used systematically as public health indicators. Regularly updating risk estimations are necessary for conditions like lung cancer whose incidence has changed substantially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.